FORT LEE, N.J., July 5 /PRNewswire-FirstCall/ -- Alpharma Inc. announced today that Einar W. Sissener has retired from the company's Board of Directors effective June 29, 2006 following over thirty years of service. Mr. Sissener served as Chairman of Alpharma's Board of Directors since the company was founded in 1975 until April 2006, and was Chief Executive Officer from 1994 to 2000.
"Alpharma has made tremendous progress in recent years," commented Mr. Sissener. "I have every confidence that, with Alpharma's current board of directors and a strong experienced management team, led by newly appointed Chief Executive Officer Dean Mitchell, Alpharma will realize its significant potential to deliver shareholder value as a recently transformed specialty pharmaceutical company. Leaving my formal board role at the company will allow me to pursue other interests, but as a significant stakeholder, I look forward to watching Alpharma's future progress in building shareholder value as it navigates a new period in its history."
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world's leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Alpharma Inc.CONTACT: Kathleen Makrakis, VP, Investor Relations, +1-201-228-5085,kathleen.makrakis@alpharma.com
Web site: http://www.alpharma.com//
